SCHEMBL4720063

SCHEMBL4720063

CCCCN(CCC)c1[c]nccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 1/20 0.35
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ELANE P08246 3/20 0.33
CRHR1 P34998 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
AGTR1 P30556 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 1/20 0.31
S1PR1 P21453 1/20 0.31
NR1H2 P55055 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724165 0.96 UTS2R (0.37) UTS2RMAPTLMNAMAPK1NPSR1
SCHEMBL4723409 0.93 AGTR1 (0.35) MAPTLMNAMEN1NPC1AGTR1
SCHEMBL4722931 0.90 MAPT (0.38) UTS2RMAPTLMNAMAPK1NPSR1
SCHEMBL4722714 0.86 KCNA5 (0.33) MAPTMEN1NPC1AGTR1RAB9A
SCHEMBL4722782 0.81 KDM4E (0.38) UTS2RMAPTKDM4EALDH1A1TDP1
SCHEMBL2067322 0.80 TAAR1 (0.34) MAPTMAPK1NPSR1KDM4EALDH1A1
SCHEMBL4723658 0.78 UTS2R (0.32) UTS2RMAPTLMNAMAPK1NPSR1
SCHEMBL4722599 0.77 CSNK1D (0.33) L3MBTL1KCNA5KCNH2
SCHEMBL4723440 0.74 UTS2R (0.33) UTS2RMAPTLMNAMAPK1NPSR1
SCHEMBL4719826 0.74 TDP1 (0.35) UTS2RMAPTLMNAMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 UTS2R 632/4885MAPT 4361/4885LMNA 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.